A New Path for US Stem Cell Inc (OTCMKTS:USRM)


US Stem Cell Inc (OTCMKTS:USRM) is working its way back after a fall last week after news broke the company abandoning RMAT designation for its Myocell product. There was a feeling that the FDA told the company that it was not going to happen and USRM tried to bury the press, but the market saw it and shares tanked.

Since then, shares have been slowly working their way back. The stock is near .06 and has scored a few rips since June 21st, when the price fell to .03. This is an early player in the industry and recently received some nice funding ($5 million from General American Capital Partners).

US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. USRM’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases.

According to company materials, “US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.”

You can find out when $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Now that Plan B is in place; however, it is a little unclear of what the ceiling is for USRM. The company will now expand stem cell treatment centers and clinics in the U.S. The company, based in Florida, had recently expanded to Miami Beach, but now the plans call for truly national expansion. USRM will set up stem cell treatment centers in huge metropolitan areas like Dallas, Chicago, Atlanta and Denver. Moreover, the company has emphasized that it will focus squarely on “revenue-generating programs” that are treating patients right now.

USRM’s press detailed the new path for the company:  “To be clear, U.S. Stem Cell will focus on our revenue generating programs that are treating patients NOW–which have successfully helped over 7000 patients thus far. Our company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world. In addition to our efforts at US Stem Cell Training and VetBiologics, our focus will be expanding and opening additional clinics throughout the U.S. to offer these cutting-edge technologies to more patients.”

US Stem Cell Inc (OTCMKTS:USRM) caught a bad break but still has strong technology and experience to hedge against the tide. USRM is not a company to completely throw out and they carry a market cap of $22.81 million with 335.43 million shares outstanding. We will be providing updates as the company take shape. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!


Please enter your comment!
Please enter your name here